- Vetter has broken ground on a new 50,000 sqm injectable drug production facility in Saarlouis, Germany.
- The company plans to invest nearly €500 million in the site, which is expected to create around 1,500 jobs by the end of the first construction phase.
Vetter has started construction of a new production facility in Saarlouis, Germany, marking an expansion of its commercial injectable drug manufacturing operations.
The company said the first construction phase includes development of a 50,000 sqm manufacturing facility designed for commercial production of injectable drugs, including cleanroom capacity for syringes and vials. Vetter stated that the site is scheduled for commissioning in 2031 and represents an investment of nearly €500 million.
According to the company, the Saarlouis facility is expected to create approximately 1,500 jobs by the final stage of the first construction phase. Representatives from regional and state government, project partners, and Vetter attended the groundbreaking ceremony.
Vetter said the project forms part of its broader strategy to strengthen manufacturing operations in Europe and the United States. The company added that the new site will support customers developing complex and innovative injectable drug products.
